Sun Pharma Advanced Research Company Limited has informed the Exchange about incorporation of wholly owned subsidiary company
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma Advanced Research Company Limited (SPARC) has incorporated a wholly owned subsidiary called Genokine Biotech Limited on July 4, 2025, with a registered office in Vadodara, Gujarat. The subsidiary has an authorized and subscribed capital of just Rs. 1 lakh, with SPARC subscribing to 10,000 equity shares of Rs. 10 each at a total cost of Rs. 1 lakh in cash. The new entity will focus on research and development activities, including support for products for human and non-human use such as veterinary, agricultural, and industrial products. This follows the board's earlier approval communicated on February 10, 2025. Since the company is newly incorporated, there is no prior turnover or operating history to report.
This is a minor internal corporate restructuring with negligible financial impact — only Rs. 1 lakh invested into a new R&D-focused subsidiary. Shareholders should not expect any material change in SPARC's business or financials from this move, though it provides the company a dedicated vehicle to pursue specific R&D activities going forward.